Lineage Cell Therapeutics, Inc. LCTX
Set alert
1.00 USD -0.03 -2.91%
At close · Oct 30
1.02 +0.02 +1.69%
After hours · Oct 30, 5:02 PM ET
0.9821 Day range 1.05
0.88 52-week range 2.09
- YTD
- -40.12%
- 1 year
- -45.65%
- Open
- 1.04
- Prev close
- 1.03
- Mkt cap
- 252.91M
- Vol
- 1.17M
- Avg vol
- 1.25M
- EPS
- -0.19
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.9821
- High
- 1.05
- Forward P/E
- -3.66
- Beta
- 1.28
- Short ratio
- 35.21
- Inst. own
- 50.56%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.7364
- 200-d avg
- 0.96025
- 1y target
- 4.83
Financial health
Altman Z-Score
-3.46 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C-1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 4
- P/E 1
- P/B 1
Valuation
P/E -6.0×
FY 2016 5y median -7.8× FY 2025
P/S 26.4×
FY 2016 5y median 21.0× FY 2025
P/B 8.6×
FY 2016 5y median 3.0× FY 2025
P/FCF -19.8×
FY 2016 5y median -6.4× FY 2025
EV/EBITDA -5.1×
FY 2016 5y median -6.9× FY 2025
EV/Sales 23.8×
FY 2016 5y median 17.4× FY 2025
FCF Yield -5.1%
FY 2016 5y median -5.9% FY 2025
Profitability
Gross Margin 94.2%
FY 2016 5y median 94.2% FY 2025
Operating Margin -149.6%
FY 2016 5y median -226.1% FY 2025
Net Margin -436.5%
FY 2016 5y median -240.2% FY 2025
ROE -142.6%
FY 2016 5y median -35.8% FY 2025
ROIC -19.7%
FY 2016 5y median -21.4% FY 2025
ROA -56.4%
FY 2016 5y median -21.3% FY 2025
Growth (YoY)
Revenue 53.2%
FY 2016 FY 2025
Operating Income -1.4%
FY 2016 FY 2025
EPS (diluted) -201.1%
FY 2016 FY 2025
Free Cash Flow 17.8%
FY 2016 FY 2025
Financial Health
Current Ratio 5.2×
FY 2016 5y median 3.2× FY 2025
Quick Ratio 5.2×
FY 2016 5y median 3.2× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.0× FY 2025
Net Debt / EBITDA 0.6×
FY 2016 5y median 1.2× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31